b-Lactam antibiotics enhance cellular glutamate uptake. As increased glutamatergic transmission is a primary mediator of opiate dependence, we tested the hypothesis that a b-lactam antibiotic (ceftriaxone) prevents development of morphine physical dependence in rats. Morphine (20 mg/kg) was injected twice daily for 10 days to induce physical dependence. Naloxone (10 mg/kg) administration 1, 48, and 96 h after the last morphine injection induced a withdrawal syndrome characterized by the appearance of wet-dog shakes, teeth chattering, eye blinking, jumping, and paw tremor. Ceftriaxone (150, 200 mg/kg) injected once daily during chronic morphine exposure inhibited each naloxone-precipitated withdrawal sign. Ceftriaxone efficacy persisted even after the 96 h-naloxone (10 mg/kg) injection. These results suggest that b-lactam antibiotics inhibit processes leading to development of morphine physical dependence.
Introduction
Glutamate activity is regulated by two categories of glutamate receptors, N-methly-D-aspartate (NMDA) and non-NMDA, and two distinct transporter systems, the high-affinity, sodium-dependent, excitatory amino acid transporters (EAATs) and the cystine-glutamate antiporter (Bridges and Esslinger, 2005) . Increased glutamate activity produced by repeated morphine (MOR) exposure mediates physical dependence, a phenomenon defined by the appearance of a withdrawal syndrome after the discontinuation of MOR exposure or administration of an opioid antagonist (Noda and Nabeshima, 2004) . NMDA receptor activation plays a critical role in MOR physical dependence as the development, expression, and maintenance of the phenomenon are inhibited by NMDA receptor antagonists (Trujillo and Akil, 1991; Popik and Skolnick, 1996) . Metabotropic glutamate (mGlu2/3) receptor activity also contributes to both development and expression of MOR physical dependence, whereas a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor activity is a major mediator of the process in infant rats (Fundytus and Coderre, 1994; Zhu and Barr, 2004) . A far less-studied -and understood -approach than glutamate receptor antagonism is EAAT activation. EAAT2, defined as glutamate-transporter subtype 1 (GLT-1) in rodents, is a particularly attractive target. GLT-1 is an astrocytic transporter, which mediates 90% of cellular glutamate uptake in the brain, underscoring its unrivaled importance in the maintenance of extracellular glutamate levels and the termination of glutamatergic transmission (Rothstein et al., 2004) . The primary reason GLT-1 activation is understudied is the lack of available compounds that activate the transporter. This perspective changed when a screen of 1040 clinically approved agents identified b-lactam antibiotics as the only pharmaceuticals that increase glutamate uptake through GLT-1 activation. Therefore, this study tested the hypothesis that ceftriaxone (CTX), a representative b-lactam antibiotic, blocks development of MOR physical dependence in rats.
Methods

Subjects
Animal-use procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (250-275 g) were housed two per cage and maintained on a 12-h light/dark cycle.
Procedure
Morphine sulphate and naloxone hydrochloride were injected subcutaneously and CTX was injected intraperitoneally. MOR (20 mg/kg) or saline (SAL) was injected twice daily for 10 days (07:00 and 19:00 h). Rats from both groups were injected once daily with either CTX (200 mg/kg) or SAL, beginning 2 days before the start of chronic MOR (or SAL) dosing. One hour after a morning injection of MOR (20 mg/kg) or SAL on day 11, the rats were injected with naloxone (10 mg/kg). The rats were injected again with naloxone (10 mg/kg) 48 and 96 h after the last MOR (20 mg/kg) or SAL injection. Immediately after naloxone administration, the rats were placed individually into test chambers consisting of boxes (50 Â 35 Â 45 cm) and five withdrawal signs (wet-dog shakes, teeth chattering, eye blinking, jumping, and paw tremor) were counted for 60 min by trained observers who were blind to treatment. Lower CTX doses (50, 100, and 150 mg/kg) were also tested.
Analysis
Two-way analysis of variance was used to identify the main effects followed by a Bonferroni's post-hoc analysis to identify differences between treatment groups. P values of less than 0.05 were considered statistically significant. 
Results
Two-way analysis of variance showed a significant drug effect for each naloxone-precipitated withdrawal sign: (Fig. 1) . The frequency of each withdrawal sign (1, 48, and 96 h) was significantly greater in rats coexposed to SAL and MOR than in earlier drug-naïve rats (SAL + SAL) or CTX-exposed rats (CTX + SAL) (P < 0.05). Rats with earlier 200-mg/kg CTX experience (CTX + SAL) did not display significantly different withdrawal signs after naloxone injection than earlier drug-naïve rats (SAL + SAL) (NS). However, the frequency of each withdrawal sign was significantly less in rats coexposed to CTX (200 mg/kg) and MOR (CTX + MOR) compared with rats exposed to MOR (SAL + MOR) (P < 0.05). The CTX (200 mg/kg) effect was evident regardless of the time of naloxone injection (P < 0.05). The CTX effect was also dose-related as pretreatment with 150 mg/kg of CTX reduced the frequency of each naloxone-precipitated withdrawal sign whereas lower CTX doses (50 and 100 mg/kg) were ineffective (Fig. 2) . 
Discussion
This study that CTX inhibits development of MOR physical dependence in rats identifies a functionally significant interaction between a b-lactam antibiotic and MOR in opiate-dependent animals. The CTX effect is likely to be related to its capacity to increase cellular glutamate uptake (Rothstein et al., 2005; Lipski et al., 2007; Rawls et al., 2007) . Glutamate transporter dysfunction and opiate dependence have been linked by evidence that chronic MOR exposure reduces GLT-1 mRNA levels in the brain and spinal cord Ozawa et al., 2004) . Our data are further supported by evidence that MOR physical dependence is reduced by MS-153, an agent that displays antiglutamatergic activity through multiple mechanisms, including glutamate uptake enhancement in CS-7 cells, voltagegated calcium channel inhibition (Nakagawa et al., 2001) , and by genetic insertion of GLT-1 mRNA into the locus coeruleus (Ozawa et al., 2004) .
It is unclear how GLT-1 transporter activation by CTX countered naloxone-precipitated MOR withdrawal signs. The development of MOR physical dependence and expression of somatic signs of MOR withdrawal are multifactorial processes, which are mediated by several neural substrates (e.g. locus coeruleus, hypothalamus) and highly dependent on the activation of central glutamate systems (Trujillo and Akil, 1991; Koob et al., 1992; Rasmussen et al., 1996) . It is well-documented that repeated CTX exposure enhances GLT-1 transporter activity, either through upregulation or independent modulation of the transporter protein (Chu et al., 2007; Lipski et al., 2007) . The most plausible explanation for this finding is that GLT-1 transporter activity is either enhanced or maintained in rats coexposed to CTX and MOR. In this case, the enhancement in cellular glutamate uptake produced by GLT-1 transporter activation inhibits the normal increase in glutamate transmission related to MOR dependence, perhaps by preventing the increase in extracellular glutamate levels produced by MOR withdrawal (Koob et al., 1992) . The site of action of CTX is unknown, but the locus coeruleus is a likely candidate. This midbrain nucleus is the most sensitive anatomical site for the expression of somatic signs of MOR withdrawal, and GLT-1 transporter overexpression in the locus coeruleus blocks naloxone-precipitated MOR withdrawal signs (Koob et al., 1992; Ozawa et al., 2004) .
It should be noted that the CTX doses (150, 200 mg/kg), which disrupted MOR physical dependence in our study, yielded brain CTX concentrations comparable with those levels required to increase GLT-1 expression (3.5 mmol/l) and attained with meningitis therapy (0.3-6 mmol/l) (Rothstein et al., 2005) . However, these doses given to rats are significantly greater than the maximal dose (2 g/day) of CTX administered to patients as an antibiotic (Chandrasekar et al., 1984) . Future studies will determine whether the CTX effect shown in these experiments is mimicked by agents that display greater clinical versatility, such as potent b-lactam antibiotics (e.g. meropenem) and nonantibiotic b-lactam compounds (e.g. b-lactamase inhibitors).
